|
|
2010 - 11 |
|
 |
Sun Pharmaceutical Sends Letter to Directors of Taro |
 |
|
|
2009 - 10 |
|
|
Taro Shareholders to Levitt and Directors: Quit the Board |
|
|
RiskMetrics Recommends Taro Shareholders Vote Against Taro Board of Directors |
|
|
Glass Lewis Advises Taro Shareholders to Hold Taros Board Accountable for its Failures |
|
|
PROXY Governance Recommends Against Taros Board and Supports Sun |
|
|
Sun Pharma Sends Letter to Taro Shareholders |
|
|
Sun Pharma announces USFDA tentative approval for generic Strattera® Capsules |
|
|
Sun Pharma announces USFDA tentative approval for generic Gleevec® tablets |
|
|
Sun Pharma announces USFDA approval for generic Acular® |
|
|
Generic Eloxatin and Imitrex approval: Shares 180-day marketing drug exclusivity for generic Eloxatin® |
|
|
Sun Pharma signs agreement with MedImmune for generic Ethyol® |
|
|
Sun Pharma to License Key Escitalopram Patent Applications to Lundbeck |
|
|
Sun Pharma announces USFDA approval for generic Casodex ® tablets |
|
|
Sun Pharma announces USFDA tentative approval for generic Optivar® |
|
|
Conference Call Transcript - FDA seizure at Caraco, June 2009 |
|
|
Sun Pharma to hold conference call on June 27, 2009 |
|
|
Sun Pharma announces USFDA approval for generic Accupril® tablets |
|
|
Sun Pharma announces USFDA tentative approval for generic Uroxatral Extended Release ® tablets |
|
|
Sun Pharma announces USFDA approval to market generic Roxicodone® tablets |
|
|
|
2008 - 09 |
|
|
Sun Pharma to announce FY09 results on May 30. Earnings call on June 1, 2009. |
|
|
Sun Pharma announces USFDA approval to market generic Topamax ® tablets |
|
|
Sun Pharma extends Tender Offer for Taro to April 3, 2009 |
|
|
Sun Pharma extends Tender Offer for Taro to Mar 20, 2009 |
|
|
Sun Pharma extends tender offer for Taro to March 6, 2009 |
|
|
Sun Pharma Q3 results on Jan 30; Conf call on Jan 31 |
|
|
Sun Pharma receives USFDA approvals for 4 generic products; Company receives its first controlled substance product approval |
|
|
Sun Pharmaceutical Extends Tender Offer for Taro to January 30, 2009 |
|
|
Sun Pharmaceutical Extends Tender Offer for Taro to January 9, 2009 |
|
|
Sun Pharma update on ANDA for generic Effexor XR: USFDA grants Osmotica's Citizen Petition |
|
|
Sun Pharma subsidiary acquires 100% of Chattem Chemicals, Inc. a US based DEA registered narcotic API importer & producer |
|
|
Sun Pharmaceutical Extends Tender Offer for Taro to Dec 19, 2008 |
|
|
Sun Pharmaceutical announces USFDA approval to market generic Sinemet® tablets |
|
|
Sun Pharma to announce Q2 and H1 2008-09 results on Oct 25, 2008 |
|
|
Sun Pharma extends Tender offer for Taro |
|
|
Sun Pharma announces USFDA approval to market generic Paraplatin® injection |
|
|
Sun Pharma gets USFDA approval for generic Fosamax ® tablets |
|
|
Sun Pharmaceutical Extends Tender Offer for Taro |
|
|
Sun to file amendment to Tender Offer for Taro Waiving certain conditions |
|
|
Tel-Aviv Court Rules in Favor of Sun Pharmaceutical; No Special Tender Offer Neccessary in Taro Offer |
|
|
Sun Pharma announces US FTC Clearance |
|
|
Sun Pharma gets USFDA approval for generic Depakote ® delayed release tablets |
|
|
Sun Pharma reaffirms commitment to Taro facilities and employees |
|
|
Sun Pharma Extends Tender Offer for Taro |
|
|
Sun Pharma Commences Tender Offer for Taro Shares |
|
|
Sun Pharma Exercises its Options to Acquire the Shares of the Controlling Shareholders of Taro Pharma |
|
|
Sun Pharmas Second Letter to Taro Pharma Regarding Taro's Irish Subsidiary |
|
|
Sun Pharma Comments on Taro’s Potential Sale of its Irish Operations |
|
|
Sun Pharma Responds to Taro’s purported Termination of Merger Agreement |
|
|
Sun Pharma receives notice for termination of merger from Taro |
|
|
Q4 2007-08 results on 30 May, 2008; earnings call on 30 May, 2008 at 6:30 PM IST |
|
|
|
2007 - 08 |
|
|
Sun Pharmaceutical announces launch of generic Ethyol® (180 days exclusivity) |
|
|
Sun Pharmaceutical announces USFDA approval to market generic Tessalon® |
|
|
Sun Pharmaceutical announces USFDA approval to market generic Cerebyx® |
|
|
Sun Pharmaceutical announces USFDA approval to market generic Ethyol® (With 180 day marketing exclusivity) |
|
|
Sun Pharma gets USFDA tentative approval for generic Gemzar® injection |
|
|
Sun Pharma gets USFDA approval to market generic Demadex® Tablets |
|
|
Sun Pharma buys additional 9.4% stake in Taro Pharma from Brandes |
|
|
Sun Pharma gets USFDA tentative approval for generic Depakote ® delayed release tablets |
|
|
Sun Pharma launches generic Protonix ® Tablets |
|
|
Sun Pharma Q3 2007-08 results on 30 Jan, 2008; earnings call on January 31, 2008 on 10:00 am IST |
|
|
Sun Pharma announces settlement of litigation over generic Exelon® |
|
|
Sun Pharma announces USFDA approval to market generic Exelon® Capsules |
|
|
Sun Pharma receives “will-not-sue” covenant on generic Effexor XR ® ANDA |
|
|
Sun Pharma 2Q 2007-08 results on Oct 25, 2007; earnings call on Oct 26 at 10 am IST |
|
|
Sun Pharma announces USFDA approval to market generic Trileptal® Tablets, 180 day marketing exclusivity |
|
|
Sun Pharma announces USFDA approval to market generic Protonix Tablets - Company gets it's first 180 day marketing exclusivity on a first-to-file ANDA with para IV certification |
|
|
USFDA grants tentative approval for Sun Pharma's ANDA for Galantamine tablets |
|
|
Sun Pharma announces USFDA approval for Sinemet CR, an extended release version of Carbidopa with Levodopa |
|
|
Sun Pharma announces USFDA approval to market generic Octreotide injection |
|
|
Investor Presentation |
|
|
Notice of Extraordinary General Meeting on July 28, 2007 |
|
|
Sun Pharma to acquire Taro Pharma in a USD 454 million deal |
|
|
Apportionment of cost between SPIL and SPARC |
|
|
Way forward on demerger |
|
|
|
2006 - 07 |
|
|
Sales growth 30%, Profit Increased 35%, R&D spend Rs. 2924 million |
|
|
Transcript of Management presentation on NCE and NDDS |
|
|
Management Presentation on NCE and NDDS |
|
|
Announcement of a Management presentation on NCE and NDDS |
|
|
Q3 Sales up 27%, Net Profit up 36% |
|
|
3rd Quarter 2006-07 Results on 29 Jan 2007, call on 30 Jan at 0930 |
|
|
Sun Pharma's lead molecule enters Phase II in the US |
|
|
Second Quarter results on Oct. 19 |
|
|
April News |
 |
|
|
2005 - 06 |
|
|
Conference call transcript- innovative R&D demerger |
|
|
Q & A demerger |
|
|
Board Clears demerger Proposal |
|
|
Conference call: Demerger |
|
|
Sun Pharma's board to meet Jan 30: Q3 results |
|
|
Sun Pharma closes Able Labs acquisition in the US |
|
|
Sun Pharma H1 results on Oct 28 |
|
|
Sun Pharma shares plans: Recent Hungarian and US Acquisitions |
|
|
Sun Pharma buys manufacturing facility in Bryan, Ohio |
|
|
Sun Pharma to buy manufacturing site in Hungary |
|
|
Sun Pharma Q1 post results Conference call on Thursday July 28 at 11am IST |
|
|
Sun Pharma Board to meet July 27 |
|
|
Q4 results on June 6, Conf call June 7 |
|
|
Sun Pharma to donate hostel for medical college |
|
|
Sun Pharma shares guidance for 2005-2006 |
|
|
|
2004 - 05 |
|
|
Quarter 4 Conference Call on April 28 at 10am |
|
|
Q3 Result Conference Call |
|
|
President to inaugurate Sun Pharma’s research center |
|
|
Sun Pharma launches additional US$75mill FCCB |
|
|
Sun Pharma declares interim dividend |
|
|
Sun Pharma completes $275 mill FCCB |
|
|
Sun Pharma launches $225 mill FCCB Issue |
|
|
Sun Pharma board to meet on Oct 21: first half results |
|
|
Sun Pharma to buy 3 US brands for $5.4 mill Entry in brand market in North America |
|
|
Fire in Unit 1 at Panoli |
|
|
Sun Pharma: Flood at Plant sites |
|
|
Sun Pharma Q1 post results Conference call on Monday, August 2 at 11.00 am |
|
|
Sun Pharma announces swap ratio for Phlox Pharma merger |
|
|
Sun Pharma board to meet July 31: Q1 results |
|
|
Sun Pharma to acquire a bulk active company :: Phlox Pharma has EDMF approval, UKMCA / USFDA compliant plant |
|
|
Fire put out at Sun Pharma’s corporate offices |
|
|
Record date for bonus is May 29 |
|
|
Buyback of 6% Cumulative Redeemable Preference Shares |
|
|
Sun Pharma's bulk active and tablet manufacturing factories are cleared by USFDA |
|
|
Letter to the stock exchange for result correction |
|
|
No such proposal, says Sun Pharma Bloomberg story titled " Sun Pharma Plans to Acquire Remaining Stake in Caraco" |
|
|
Sun Pharma Q4 post results Conference call on Thursday April 22, 12 noon |
|
|
Sun Pharma board to meet April 21: Audited financial results |
|
|
Sun Pharma to raise $350mill, EGM announced |
|
|
Sun Pharma board to meet; to consider issue of convertible debentures |
|
|
Sun Pharma hikes stake in Caraco to 63.14% |
|
|
|
2003 - 04 |
|
|
1:1 Bonus announced Exports jumps 48%; powers profit growth PAT up 21.2%, Total income up 20.8%, R&D expense 11.7% of turnover |
|
|
Clarification on news items regarding acquisition of HAL |
|
|
Sun Pharma purchases additional stake in Caraco to hold over 60 % equity |
|
|
Mr. Ashwin Dani joins Sun Pharma board |
|
|
Q3 results conf call Jan 28/5pm IST |
|
|
Unaudited Q3 numbers on January 28 |
|
|
Sun Pharma H1 post results Conference call on Wednesday October 22, 11am |
|
|
Sun Pharma to announce unaudited H1 numbers on October 21 |
|
|
Conference call after the Q1 results on Monday, July 28 |
|
|
Sun Pharma to announce unaudited q1 numbers on July 28 |
|
|
|
2002 - 03 |
|
|
Sun Pharma Conference call after the Q1 results on Monday, July 28 |
|
|
Q4 conf call on May5 |
|
|
Sun Pharma to announce audited q4 numbers on May 3 |
|
|
DMF approval for Metaprolol tartrate received |
|
|
Q3 conf call announcement for Jan 30 |
|
|
Q3 numbers on January 30 |
|
|
EGM clears resolutions for split, buyback |
|
|
Sun Pharma board proposes buyback plan |
|
|
Q2 Results on October 28, 2002 |
|
|
Biostudy volunteer in hospital with pneumonia |
|
|
Mr Keki Mistry joins Sun Pharma's Board of directors |
|
|
AGM approves bonus preference. |
|
|
Conference call after the Q1 unaudited numbers on Monday, July 22 |
|
|
Sun Pharma launches anticancer with novel biodegradable microsphere technology Product readily available at distribution centers, first time in India |
|
|
Sun Pharma announces Bonus Preference Shares carrying coupon of 6% in ratio of 4 shares of Rs 1/- each per 1 equity share held |
|
|
|
2001 - 02 |
|
|
Sun Pharma announces audited numbers, dividend, bonus preference, M J Pharma swap record date |
|
|
Sun Pharmas board to meet: audited accounts, MJ Pharma merger |
|
|
Earnings conference call |
|
|
Offer Letter to Shareholders-Regional Stock Exchanges delisting |
|
|
Sun Pharma's new plant at Dadra commences operations |
|
|
Sun Pharma launches Smoquit |
|
|
|
2000 - 01 |
|
|
Hasmukh Shah joins Sun Pharma board |
|
|
PDC ratio is 500 : 1. |
|
|
Board to meet to consider merger of Pradeep Drugs. |
|
|
Sun Pharma clarifies on news stories. |
|
|
|
1999 - 00 |
|
|
Sun Pharma board to consider merger of Export subsidiary |
|
|
Press release for second interim dividend |
|
|
Sun Pharma declares 40% second interim dividend |
|
|
Press release for the bonus share issue |
|
|
Sun Pharma announces bonus |
|
|
Sun Pharma board to consider bonus on Feb 1 |
|
|
Press release for the merger of Milmet Laboratories Pvt. Ltd. |
|
|
Sun Pharma declares 60% interim dividend |
|
|
Sun Pharma to set up new research campus in Chennai |
|
|
Press release for the proposed research campus at Chennai |
|
|
CLARIFICATION- No intimation from BIFR |
|
|
CLARIFICATION Chennai Plant |
|
|
BIFR Okays GLOL merger |
|
|
|
1998 - 99 |
|
|
AGM Speech-Dec1999 |
|
